ONCY:NASDAQ, Oncolytics Biotech Inc.
ONCY stock overview
Oncolytics Biotech Inc. (ONCY:NASDAQ) closed at $0.382 on November 10, 2026,
down 6.35% on the day.
The stock trades 70.6% below its 52-week high of $1.30
and 0.5% above its 52-week low of $0.380.
Over the past year, it lost 61.9%.
Oncolytics Biotech Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $0.382
- Day change
- -6.35%
- Volume
- 542,463
- Average volume
- 1,083,759
- Market cap
- 50M+
- 52-week range
- $0.380 – $1.30
- 50-day average
- $0.616
- 200-day average
- $0.843
Price action over the past year
In 252 trading sessions since November 10, 2025, ONCY closed higher on 88 days (35%).
Its best day was February 13, 2026 (+27.71%) and its worst was October 12, 2026 (-16.07%).
The stock moved 10% or more in a single session 15 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
ONCY news
-
Nov 9, 2026:
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
-
Nov 4, 2026:
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
-
Oct 27, 2026:
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
-
Oct 27, 2026:
Oncolytics Biotech Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
-
Oct 20, 2026:
Oncolytics Biotech to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
-
Oct 20, 2026:
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
-
Oct 14, 2026:
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
-
Oct 14, 2026:
Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer that have not been successfully treated with conventional therapeutics.
Similar stocks
Find more stocks like ONCY with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.